# Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/canakinumab-versus-placebo-in-combination-with-first-line-pembrolizumab-plus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Daniel S.W. Tan,Enriqueta Felip,Gilberto de Castro,Benjamin Solomon,Alastair Greystoke,Byoung Chul Cho,Manuel Cobo,Tae Min Kim,Sandip Ganguly,Enric Carcereny,Luis Paz‐Ares,Jaafar Bennouna,Marina Chiara Garassino,Michael Schenker,Sang‐We Kim,Jan C. Brase,Denise Bury-Maynard,Vanessa Q. Passos,Stéphanie Deudon,Bharani Dharan,Yuanbo Song,Rafael Caparica,Bruce E. Johnson |
| Citations | 83 |
| DOI | 10.1200/jco.23.00980 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4389243374 |
| PMID | 38039427 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Sandip Ganguly](https://scholariq.org/researchers/sandip-ganguly/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.